Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ampakine
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase II
Sponsor : Department of Defense
Deal Size : $1.8 million
Deal Type : Funding
RespireRx Pharmaceuticals Receives DOD Award for Phase 2 Study on CX1739 in Spinal Injury
Details : RespireRx intends to use the net proceeds to fund phase 2 clinical study of CX1739, its Lead AMPAkine, to improve bladder function in patients with spinal cord injury.
Brand Name : CX1739
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 29, 2024
Lead Product(s) : Ampakine
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase II
Sponsor : Department of Defense
Deal Size : $1.8 million
Deal Type : Funding
Lead Product(s) : KRM-II-81
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
RespireRx Reports Preclinical Pain Relief for Non-Opioid Lead GABAkine Product
Details : KRM-II-81 is an orally bioavailable imidazodiazepines that acts as a GABA-A receptor potentiator (GABAkine). It is being developed for the treatment of pain.
Brand Name : KRM-II-81
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 13, 2024
Lead Product(s) : KRM-II-81
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Tetrahydrocannabinol
Therapeutic Area : Sleep
Study Phase : Phase II
Sponsor : ResolutionRx
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, ResolutionRx will use and exploit the Licensed IP associated with new dronabinol formulations initially to be developed for the treatment of obstructive sleep apnea.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 09, 2023
Lead Product(s) : Tetrahydrocannabinol
Therapeutic Area : Sleep
Highest Development Status : Phase II
Sponsor : ResolutionRx
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Ampakine
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Preclinical
Sponsor : University College London
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration aims to to study the possibility of using CX1739, RespireRx’s lead clinical AMPAkine, for the treatment of a major class of GRIA disorders.
Brand Name : CX1739
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 05, 2023
Lead Product(s) : Ampakine
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Preclinical
Sponsor : University College London
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : KRM-II-81
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The compounds described in these articles were efficacious as anticonvulsants and the most characterized of these, KRM-II-81, KPP-III-34, displayed robust activity in more advanced anti-seizure models. All compounds were effective without producing sedat...
Brand Name : KRM-II-81
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 03, 2023
Lead Product(s) : KRM-II-81
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : KRM-II-81
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : KRM-II-81 analogs enhances the GABAergic neurotransmission and function as orally-bioavailable anti-seizure agents in the absence of the sedation typically associated with GABA augmentation.
Brand Name : KRM-II-81
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 03, 2023
Lead Product(s) : KRM-II-81
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Tetrahydrocannabinol
Therapeutic Area : Sleep
Study Phase : Phase II
Sponsor : University of Illinois
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : D9-THC (dronabinol, D9-tetrahydrocannabinol) is an oral capsule drug product that is being tested for clinical efficacy in patients with obstructive sleep apnea (OSA).
Brand Name : D9-THC
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 23, 2023
Lead Product(s) : Tetrahydrocannabinol
Therapeutic Area : Sleep
Highest Development Status : Phase II
Sponsor : University of Illinois
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Tetrahydrocannabinol
Therapeutic Area : Sleep
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Dronabinol, delta-9-THC, is a synthetic version of the naturally occurring substance in the cannabis plant. Drug is an endocannabinoid CB1 and CB2 receptor agonist which is being developed for the treatment of Obstructive sleep apnea.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 12, 2023
Lead Product(s) : Tetrahydrocannabinol
Therapeutic Area : Sleep
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : KRM-II-81
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : National Institute for Neurological Disorders and Stroke
Deal Size : Undisclosed
Deal Type : Collaboration
Details : GABAkine, KRM-II-81, has been shown to be effective in relieving acute, chronic, and neuropathic pain without tolerance development. KRM-II-81 preferentially bound to specific subtypes of GABAA receptors to inhibit pain sensory neurons in the spinal dors...
Brand Name : KRM-II-81
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 05, 2022
Lead Product(s) : KRM-II-81
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : National Institute for Neurological Disorders and Stroke
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Tetrahydrocannabinol
Therapeutic Area : Sleep
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : RespireRx’s ResolutionRx business unit is developing dronabinol, ∆-9-THC, a synthetic version of the naturally occurring substance in the cannabis plant, for the treatment of OSA.
Brand Name : ResolutionRx
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 08, 2022
Lead Product(s) : Tetrahydrocannabinol
Therapeutic Area : Sleep
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?